{"id":"https://openalex.org/W2173235643","doi":"https://doi.org/10.1158/1078-0432.ccr-15-1295","title":"Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example","display_name":"Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example","alternate_titles":[],"publication_year":2015,"publication_date":"2015-11-23","ids":{"openalex":"https://openalex.org/W2173235643","doi":"https://doi.org/10.1158/1078-0432.ccr-15-1295","mag":"2173235643","pmid":"https://pubmed.ncbi.nlm.nih.gov/26597302"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-15-1295","doi":"https://doi.org/10.1158/1078-0432.ccr-15-1295","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-15-1295","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2173235643"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021432816","display_name":"Jeffrey R. Sachs","orcid":"https://orcid.org/0000-0001-5725-558X","observed_orcids":["https://orcid.org/0000-0001-5725-558X"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey R. Sachs","raw_affiliation_strings":["1Department of PPDM-Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of PPDM-Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Kenilworth, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055746516","display_name":"Kapil Mayawala","orcid":"https://orcid.org/0000-0001-7959-4881","observed_orcids":["https://orcid.org/0000-0001-7959-4881"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kapil Mayawala","raw_affiliation_strings":["2Department of PPDM-Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of PPDM-Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035418245","display_name":"Satvik Gadamsetty","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Satvik Gadamsetty","raw_affiliation_strings":["3Department of Clinical & Scientific Informatics and EDDS IT, Merck & Co., Inc., Rahway, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Clinical & Scientific Informatics and EDDS IT, Merck & Co., Inc., Rahway, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109399966","display_name":"Soonmo Peter Kang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Soonmo Peter Kang","raw_affiliation_strings":["4Department of Clinical Oncology, Merck & Co., Inc., Rahway, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Clinical Oncology, Merck & Co., Inc., Rahway, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5076595940","display_name":"Dinesh P. de Alwis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dinesh P. de Alwis","raw_affiliation_strings":["2Department of PPDM-Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of PPDM-Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":null,"apc_paid":null,"fwci":1.9239,"has_fulltext":false,"cited_by_count":165,"citation_normalized_percentile":{"value":0.87113402,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"22","issue":"6","first_page":"1318","last_page":"1324"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.9711999893188477,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.9711999893188477,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.008700000122189522,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6259999871253967},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.7599999904632568},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7639999985694885},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8840000033378601},{"id":"https://openalex.org/keywords/dose-ranging-study","display_name":"dose-ranging","score":0.5680000185966492},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.578000009059906},{"id":"https://openalex.org/keywords/target-engagement","display_name":"target engagement","score":0.5720000267028809},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8759999871253967},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.9020000100135803},{"id":"https://openalex.org/keywords/anticancer-drug-development","display_name":"anticancer drug development","score":0.6330000162124634},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.5239999890327454},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.8700000047683716}],"concepts":[{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.8646990060806274},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7877435684204102},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5518779754638672},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5390095114707947},{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.4822845757007599},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4574829936027527},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4573154151439667},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.44009581208229065},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.438785195350647},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.43758174777030945},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.43731677532196045},{"id":"https://openalex.org/C2781047461","wikidata":"https://www.wikidata.org/wiki/Q679692","display_name":"Biopharmaceutical","level":2,"score":0.4210716784000397},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.41857367753982544},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.39656421542167664},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3841404616832733},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3772971034049988},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-15-1295","doi":"https://doi.org/10.1158/1078-0432.ccr-15-1295","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-15-1295","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:26597302","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26597302","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332521","display_name":"University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W102795491","https://openalex.org/W1061111608","https://openalex.org/W1705006587","https://openalex.org/W1939364580","https://openalex.org/W1963919702","https://openalex.org/W1970974693","https://openalex.org/W1974643012","https://openalex.org/W1977246223","https://openalex.org/W1982189141","https://openalex.org/W2000482060","https://openalex.org/W2024963690","https://openalex.org/W2041710964","https://openalex.org/W2043911652","https://openalex.org/W2052874737","https://openalex.org/W2075131732","https://openalex.org/W2093520916","https://openalex.org/W2095447519","https://openalex.org/W2098550014","https://openalex.org/W2104830962","https://openalex.org/W2109895173","https://openalex.org/W2112762770","https://openalex.org/W2115499099","https://openalex.org/W2116171965","https://openalex.org/W2122956665","https://openalex.org/W2123855420","https://openalex.org/W2135157520","https://openalex.org/W2136146667","https://openalex.org/W2139499843","https://openalex.org/W2150048477","https://openalex.org/W2165487575","https://openalex.org/W2171497508","https://openalex.org/W2413774612","https://openalex.org/W3115943439"],"related_works":["https://openalex.org/W2018723375","https://openalex.org/W2273124893","https://openalex.org/W2947201178","https://openalex.org/W2885249447","https://openalex.org/W2415972817","https://openalex.org/W4291327281","https://openalex.org/W3172276978","https://openalex.org/W4381149229","https://openalex.org/W7161598734","https://openalex.org/W2099190146"],"abstract_inverted_index":{"One":[0,88],"of":[1,5,52,135,180,220,240],"the":[2,14,133,147,156,159,171,175],"key":[3,178],"objectives":[4],"oncology":[6,150,226],"first-in-human":[7],"trials":[8,201],"has":[9,137],"often":[10],"been":[11,138],"to":[12,43,78,92,166,189,234],"establish":[13],"maximum":[15],"tolerated":[16],"dose":[17,56,81,97,163,184,223],"(MTD).":[18],"However,":[19],"targeted":[20,65],"therapies":[21],"might":[22],"not":[23],"exhibit":[24],"dose-limiting":[25],"toxicities":[26],"(DLT)":[27],"at":[28],"doses":[29],"significantly":[30],"higher":[31],"than":[32],"sufficiently":[33],"active":[34],"doses,":[35],"and":[36,158,170],"there":[37],"is":[38,91],"frequently":[39],"a":[40,84,94,108,209,229,235,241],"limited":[41],"ability":[42],"objectively":[44],"quantify":[45],"adverse":[46],"events.":[47],"Thus,":[48],"while":[49],"MTD-based":[50],"determination":[51],"recommended":[53],"phase":[54,243],"II":[55,244],"may":[57],"have":[58,208],"yielded":[59],"appropriate":[60],"dosing":[61,190,195],"for":[62,83,120,128],"some":[63,129],"cytotoxics,":[64],"therapeutics":[66],"(including":[67],"monoclonal":[68],"antibodies":[69],"and/or":[70],"immunotherapies)":[71],"sometimes":[72],"need":[73],"alternative":[74],"or":[75,112,123,217],"complementary":[76,89],"strategies":[77,165],"help":[79],"identify":[80],"ranges":[82],"randomized":[85],"dose-ranging":[86,237],"study.":[87],"strategy":[90],"define":[93],"biologically":[95],"efficacious":[96],"(BED)":[98],"using":[99],"an":[100],"\"effect":[101],"marker.\"":[102],"An":[103],"effect":[104,181],"marker":[105,115],"could":[106],"be":[107,192],"target":[109],"engagement,":[110],"pharmacodynamic,":[111],"disease":[113],"progression":[114],"(change":[116],"in":[117,145,183,199,203,225],"tumor":[118],"size":[119],"solid":[121],"tumors":[122],"bone":[124],"marrow":[125],"blast":[126],"count":[127],"hematologic":[130],"tumors).":[131],"Although":[132,174],"concept":[134],"BED":[136],"discussed":[139],"extensively,":[140],"we":[141],"review":[142],"specific":[143],"examples":[144,160,176],"which":[146,206],"approach":[148,188],"influenced":[149],"clinical":[151,204],"development.":[152],"Data":[153],"extracted":[154],"from":[155],"literature":[157],"support":[161],"improving":[162],"selection":[164,224],"benefit":[167],"patients,":[168],"providers,":[169],"biopharmaceutical":[172],"industry.":[173],"illustrate":[177],"contributions":[179],"markers":[182],"selection,":[185],"no":[186],"one-size-fits-all":[187],"can":[191,196,207],"justified.":[193],"Higher-than-optimal":[194],"increase":[197],"toxicity":[198],"later":[200],"(and":[202],"use),":[205],"negative":[210],"impact":[211],"on":[212],"efficacy":[213],"(via":[214],"lower":[215],"adherence":[216],"direct":[218],"sequelae":[219],"toxicities).":[221],"Proper":[222],"should":[227],"follow":[228],"multifactorial":[230],"decision":[231],"process":[232],"leading":[233],"randomized,":[236],"study":[238],"instead":[239],"single":[242],"dose.":[245]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2173235643","counts_by_year":[{"year":2026,"cited_by_count":18},{"year":2025,"cited_by_count":18},{"year":2024,"cited_by_count":24},{"year":2023,"cited_by_count":13},{"year":2022,"cited_by_count":15},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":14},{"year":2019,"cited_by_count":17},{"year":2018,"cited_by_count":15},{"year":2017,"cited_by_count":14},{"year":2016,"cited_by_count":10}],"updated_date":"2026-11-18T13:11:19.462570","created_date":"2016-06-24T00:00:00"}
